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Abstract
Background: Prostate tumours are commonly poorly oxygenated which is associated with tumour progression
and development of resistance to chemotherapeutic drugs and radiotherapy. Fibroblast growth factor 8b (FGF8b)
is a mitogenic and angiogenic factor, which is expressed at an increased level in human prostate tumours and is
associated with a poor prognosis. We studied the effect of FGF8b on tumour oxygenation and growth parameters
in xenografts in comparison with vascular endothelial growth factor (VEGF)-expressing xenografts, representing
another fast growing and angiogenic tumour model.
Methods: Subcutaneous tumours of PC-3 cells transfected with FGF8b, VEGF or empty (mock) vectors were
produced and studied for vascularity, cell proliferation, glucose metabolism and oxygenation. Tumours were
evaluated by immunohistochemistry (IHC), flow cytometry, use of radiolabelled markers of energy metabolism ([
18F]
FDG) and hypoxia ([
18F]EF5), and intratumoral polarographic measurements of pO2.
Results: Both FGF8b and VEGF tumours grew rapidly in nude mice and showed highly vascularised morphology.
Perfusion studies, pO2 measurements, [
18F]EF5 and [
18F]FDG uptake as well as IHC staining for glucose transport
protein (GLUT1) and hypoxia inducible factor (HIF) 1 showed that VEGF xenografts were well-perfused and
oxygenised, as expected, whereas FGF8b tumours were as hypoxic as mock tumours. These results suggest that
FGF8b-induced tumour capillaries are defective. Nevertheless, the growth rate of hypoxic FGF8b tumours was
highly increased, as that of well-oxygenised VEGF tumours, when compared with hypoxic mock tumour controls.
Conclusion: FGF8b is able to induce fast growth in strongly hypoxic tumour microenvironment whereas VEGF-
stimulated growth advantage is associated with improved perfusion and oxygenation of prostate tumour xenografts.
Background
Hypoxia is a common feature of prostate tumours [1].
A low oxygen concentration is known to make tumour
cells resistant to radiation therapy and chemotherapy
[2]. Furthermore, there is evidence that hypoxia may
lead to increasingly malignant behaviour of tumour
cells [3,4]. Hypoxia leads to disruption of microenvir-
onmental homeostasis in tumours, where metabolic
changes, involving diffusion gradients of oxygen and
glucose, develop at microregional level [5]. A common
feature of invasive cancers is altered glucose metabo-
lism, including both aerobic and anaerobic glycolysis
[6]. Conversion of glucose to lactic acid in the pre-
sence of oxygen is known as aerobic glycolysis or the
“Warburg effect”. The molecular mechanisms leading
to upregulated glycolysis in tumours are not well
known, but increased glucose uptake and elevated
expression of glucose transporters (GLUTs), such as
GLUT1, are commonly seen in tumour cells [7]. In
prostate cancer, the expression of GLUT1 is also cor-
related with Gleason score [8]. Members of the GLUT
gene family are known to be regulated by hypoxia-
inducible transcription factor 1 (HIF1), which is
strongly upregulated under hypoxic conditions [9].
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esis which is primarily stimulated by HIF1-induced vascu-
lar endothelial growth factor (VEGF) but also by other
tumour cell produced cytokines and growth factors
including fibroblast growth factors (FGFs) [10,11]. Regard-
less of neovascularisation, tumours are often poorly oxyge-
nated due to disorganised and leaky vessels [2]. VEGF is a
mitogen for vascular endothelial cells but not for other
cell types [12,13]. It induces a strong angiogenic response
in different in vivo models and increases vascular perme-
ability, which is essential to angiogenesis associated with
tumour growth and wound healing [14]. In human pros-
tate cancer patients, the expression of VEGF correlates
with Gleason score and occurrence of lymph node metas-
tasis [15,16] as well as the poor outcome of radical treat-
ment of localised prostate cancer [17].
T h ef a m i l yo fF G F sp l a y sa ni m p o r t a n tr o l ei nm a n y
physiological processes including development [18],
wound healing [19], angiogenesis [20], bone formation
and osteoblast differentiation [21]. Studies of our own
and others on FGF8 have shown that reciprocal FGF/
FGF receptor mediated interactions between tumour
cells and stromal cells play important roles in prostate
cancer progression and angiogenesis [20,22-26]. Fibro-
blast growth factors 1, 2, 6, 9 and 17 are also expressed
at high levels in prostate cancer, where they may func-
tion as paracrine and/or autocrine mediators [22,27].
Fibroblast growth factor 8 was originally cloned from
conditioned medium of mouse mammary tumour-derived
SC-3 cells and was identified as androgen-induced growth
factor (AIGF) [28]. Four human FGF8 isoforms, named
FGF8a, FGF8b, FGF8e and FGF8f, are formed by alterna-
tive splicing [29]. FGF8b has been found to be the most
transforming of these isoforms and FGF8b targeted to
prostate epithelium causes prostatic intraepithelial neopla-
sia (PIN) lesions in transgenic mice [30]. FGF8b is also the
major isoform expressed in prostate cancer [17,26,31,32].
FGFs mediate their effects by binding to specific tyrosine
kinase receptors (FGFR1-4), which all are expressed in
prostate cancer [18,33]. The in vitro and in vivo studies
have shown that FGF8b increases growth, invasion, tumor-
igenesis, angiogenesis and bone metastasis in experimental
breast [23,34,35] and prostate cell lines and tumours
[20,36-38]. FGF8b is a strongly angiogenic factor, which
property has been considered to contribute to increased
tumour growth [20,23]. In human prostate cancer, the
expression of FGF8b has been shown to predict a poor
prognosis [17,32].
We aimed to study whether FGF8b-induced rich neo-
vascularisation is able to influence oxygenation of pros-
tate tumour microenvironment and influence tumour
growth by these mechanisms. PC-3 cells were used to
create models for prostate cancer expressing VEGF or
FGF8b, which both are known to be angiogenic and to
be increased in prostate cancer. Nude mice were subcu-
taneously inoculated with PC-3 cells transfected with
FGF8b, VEGF or empty vectors. PC-3/VEGF cells were
used as “positive” controls because they were expected
to produce well-vascularised and oxygenised tumours.
The FGF8b tumours were studied for growth rate,
vascularisation, energy metabolism as well as tumour
hypoxia and oxygenation, and the findings were com-
pared with those from VEGF and mock tumours, which
served as positive and negative controls, respectively.
Methods
Cell culture and transfection
The human hormone-resistant prostate cancer cell line
PC-3 was obtained from the American Tissue-Type Cul-
ture Collection (Rockville, MD, USA). PC-3 cells, which
were stably transfected with FGF8b (PC-3/FGF8b) were
used as previously described [38]. Stable VEGF transfec-
tion was carried out by using the expression vector
pcDNA3.1(+) (Invitrogen, CA, USA) containing human
VEGF cDNA in an ECORI site (kindly provided by Prof.
Kari Alitalo, University of Helsinki, Finland, [39]) and
empty pcDNA3.1(+) vector-transfected cells (mock) were
used as controls. Neomycin (G418, 500 μg/mL) was
added to culture media of transfected PC-3 cells for the
selection of clones. At near confluence, the cells were
harvested in trypsin/EDTA (Biochrom AG, Germany),
washed with culture medium and finally suspended at a
concentration of 1 × 10
6/100 μL in sterile phosphate-buf-
fered saline solution (PBS, Biochrom AG, Germany). The
cells were kept on ice until inoculation.
Northern and Western blot analysis
Total RNA was extracted from PC-3 cells using the gua-
nidinium isothiocyanate method [40]. Northern blotting
was performed as previously described [41]. Serum-free
DMEM conditioned by FGF8b, VEGF and mock cells
was harvested from the cultures as previously described
[42]. Heparin-sepharose-bound proteins were extracted
by 5-min incubation in Laemmli sample buffer at 95°C
and separated by sodium dodecyl sulphate-polyacryla-
mide gel electrophoresis. After transfer to nitrocellulose
membranes (Bio-Rad), proteins were detected by using
goat polyclonal anti-FGF8b neutralising antibodies [20]
and anti-human VEGF antibodies (both from R&D sys-
tems, Minneapolis, MN, USA). Horseradish peroxidase-
labelled anti-goat IgG (DAKO, Denmark) was used as a
secondary antibody. Protein bands were visualised by
using an ECL chemiluminescence detection system (GE,
Healthcare Biosciences, Uppsala, Sweden).
Animals and tumour models
Eight-week-old male athymic nu/nu mice (Harlan,
the Netherlands) were maintained under controlled
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30-60% relative humidity and a 12-hour lighting cycle).
FGF8b, VEGF and mock cells were inoculated subcuta-
neously (1 × 10
6 cells in 100 μLP B S )i n t ot h eb a c ko f
the neck. The animals were monitored daily for clinical
signs. Tumour measurements were performed once a
week and tumour volume was calculated according
to the formula V = (π/6)(d1 ×d 2)
3/2 [43], where d1 and
d2 are perpendicular tumour diameters. The tumour
v o l u m ew a se x p r e s s e da sm e a n±S E M .T h ea n i m a l
experiments were carried out according to the
European Convention for the Protection of Vertebrate
Animals used for Experimental and other Scientific
Purposes, plus Statutes 1076/85 § and 1360/90 of The
Animal Protection Law in Finland, and EU Directive
86/609. The experiment procedures were reviewed by
the local Ethics Committee on Animal Experimenta-
t i o na tt h eU n i v e r s i t yo fT u r k ua n da p p r o v e db yt h e
local Provincial State Office of Western Finland.
Tumour morphology and immunohistochemical analyses
Morphological evaluation of tumours was determined
from frozen sections stained with haematoxylin and
eosin (H&E) using standard techniques. Frozen sections
(10 μM) were cut, and fixed with ice-cold acetone for
10 minutes at 4°C. Sequential frozen sections were incu-
bated with antibodies against CD31 (BD Biosciences,
Pharmingen, CA, USA), Ki67 (Novocastra Laboratories
Ltd., Newcastle upon Tyne, UK) and GLUT1 (Alphadiag-
n o s t i c s ,T X ,U S A )o / na t4 ° C .H I F 1( B DB i o s c i e n c e s ,
Pharmingen, CA, USA) antibody was used on formalin-
fixed, paraffin-embedded tumour slides o/n at 4°C. The
samples were then treated with biotin-labelled rabbit
anti-mouse (DAKO Denmark A/S, Glostrup, Denmark or
Vectastain CA, USA) secondary antibodies. A mouse-on-
mouse kit (Vector Laboratories, Burlingame, CA, USA)
was used in the Ki67 antibody staining procedure in
order to inhibit non-specific staining of anti-mouse sec-
ondary antibodies. Visualisation of the primary antibodies
was carried out by using Vectastain ABC reagent and a
diaminobenzidine substrate kit (Vector Laboratories,
Burlingame, CA, USA), the methodology which is based
on the indirect streptavidin-biotin method. The slides
were later counterstained with Meyer’s haematoxylin.
Negative controls (sections of every sample stained with-
out the primary antibody) were used to verify the specifi-
city of staining. Three representative non-overlapping
fields inside each tumour were analysed microscopically
(Leica, DMRB, Leica Microsystems, Heerburg, Germany)
and images were taken with a digital camera (Leica DC
300F, Leica Microsystems, Heerburg, Germany). The
lengths of CD31-positive vessels were counted in each
tumour by drawing lines following stained vessels and
measuring the length of the lines using ImageJ software
(ImageJ, 1.37v, Wayne Rasband, National Institutes of
Health, USA) [44]. The relative numbers of Ki67-
and GLUT1-positive cells were counted in three non-
overlapping sections at 500-μm intervals. Altogether,
1.000-3.000 cells/tumour were counted [44]. The results
were blind-tested by two independent analysers compar-
ing study versus control samples.
The relative proportion of necrotic tissue was deter-
mined in representative H&E-stained tumour slides
using the ImageJ software. The evaluation was based on
morphological features of the tissue.
The perfusion marker Hoechst 33342 was intrave-
nously injected into tumour-bearing nude mice two
minutes before sacrifice in order to study the intratu-
moral perfusion pattern. Images were acquired from fro-
zen sections (10 μm) using a Zeiss AxioVert 200 M
fluorescence microscope (Zeiss GmbH, Jena, Germany).
Flow cytometry
Three tumours from each group were collected in ice-
cold PBS supplemented with pepsin (0.5%, pH 1.4,
Merck, Darmstadt, Germany) immediately after sacrifice
of the mice. Tumour tissue was homogenised with
Ultra-Turrax equipment (Rose Scientific Ltd., Canada)
and incubated at 37°C for 1 h. The suspension was col-
lected and filtered prior to analysis. For cell cycle analy-
sis, tumour homogenate was incubated in hypotonic
buffer (PBS with 1% Triton X-100 and propidium iodide
at 0.05 mg/mL) for 20 min at 4°C. The fractions of cell
cycle phases (G0/G1, S and G2/M) were calculated with
ModFit cell cycle modelling software (Verity Software
House, Inc., Topsham, ME, USA). For cell enumeration,
cells were analysed using TrueCount tubes (Becton
Dickinson, CA, USA). Briefly, the number of cells in the
tube was calculated by comparing a known number of
beads in the tube with cell number in a known volume.
All flow cytometry was performed using a FACSCalibur
(Becton Dickinson, CA, USA) flow cytometer and Cell-
QuestPro software (Becton Dickinson, CA, USA).
[
18F]EF5 and [
18F]FDG uptake in tumours
18F-labelled EF5 (2-(2-nitro-1H-imidazol-1-yl)-N-
(2,2,3,3,3-pentafluoropropyl)-acetamide) was synthesised
from 2-(2-nitro-1H-imidazol-1-yl)-N-(2,3,3-trifluoroal-
lyl)-acetamide using high specific radioactivity
18F-F2 as
the labelling reagent [45]. The specific radioactivity of
[
18F]EF5, decay corrected to the end of synthesis,
exceeded 3.7 GBq/μmol. Radiochemical purity was
higher than 98.5% in every production batch.
18F-
labelled FDG (2-Deoxy-2-fluoro-D-glucose) was synthe-
sised from mannosyl triflate using a nucleophilic
method. Radiochemical purity exceeded 95% and speci-
fic radioactivity was approximately 74 GBq/μmol at the
end of synthesis.
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18F]EF5 (FGF8b n = 11, VEGF n =1 2a n dm o c kn =
29) and [
18F]FDG (FGF8b n =6 ,V E G Fn =6a n dm o c k
n = 5) were intravenously injected (5.6 ± 1.1 and 6.6 ±
1.4 MBq, respectively) into separate FGF8b (tumour
weight 408 ± 33 mg), VEGF (tumour weight 506 ±
29 mg), and mock (tumour weight 408 ± 20 mg) tumour-
bearing mice, and allowed to distribute 120 minutes
before sacrifice. Blood, obtained by cardiac puncture, and
tumour tissues were rapidly removed, counted for
18F-
radioactivity in a well counter (3” ×3 ” NaI (TI) crystal,
Bicron 3MW3/3P, Bicron Inc., Newbury, Ohio, USA) and
weighed. The uptake of
18F-radioactivity in tissues was
calculated as percentage of injected dose per gram of tis-
sue weight, taking into account the background from the
counter measurements and the radioactivity decay.
Tumour-to-blood uptake ratios (T/B ratios) were then
calculated for both [
18F]EF5 and [
18F]FDG. Plasma glu-
cose levels were measured (Analox GM9, Analox Instru-
ments Ltd., London, UK) in blood samples (FGF8b n =
10, VEGF n = 16 and mock n = 11).
The intratumoral distribution of [
18F]EF5 and [
18F]
FDG was studied in FGF8b, VEGF and mock tumour-
bearing mice using digital autoradiography. After sacri-
fice, tumours were removed, rapidly frozen in dry ice/
isopentane and cut with a cryomicrotome into 20 μm-
thick sections. Tumour sections were then exposed to
an imaging plate (Fuji BAS TR2025, Fuji Photo Film
Co., Japan) for 3.5-4.5 hours. The spatial distribution of
radioactivity from tumour sections was recorded with a
phosphoimager (Fujifilm BAS-5000, Fuji Photo Film Co.
Ltd., Tokyo, Japan). The dynamic linear range of this
system is four decades, and the resolution (i.e. pixel
size) of the images is 25 × 25 μm.
The amount of 2-[
18F]fluoro-2-deoxyglucose-6-
phosphate ([
18F]FDG-6-P), the main metabolite of [
18F]
FDG, was determined in tumour homogenates (FGF8b
n =6 ,V E G Fn = 4 and mock n = 3) from animals injected
with [
18F]FDG by using radioHPLC equipment (Merck
Hitachi, Peterlee, UK).
Oxygen partial pressure (pO2) measurement
In order to measure pO2 values in tumours, we used
sterile, flexible polarographic electrodes (diameter 0.47
mm) of the Clark type (Licox® GMS, Kiel-Mielkendorf,
Germany), supplied with a probe-specific microchip
allowing automatic calibration. The probe was inserted
i n t ot h et u m o u rt i s s u eb ya d v a n c i n gi ti nar e t r o g r a d e
manner along the lumen of an insertion needle catheter,
which was then removed. Tissue temperature was mea-
sured with a needle probe and temperature-adjusted
pO2 (mmHg) was graphically displayed and stored digi-
tally. The whole length of the oxygen-sensitive part of
the probe was at least 2 mm inside the tumour through-
out the measurements to prevent contamination from
room-air O2. The duration of the pO2 measurement was
sufficient to establish a stable pO2 level, which was then
registered and stored. Three tumours from each group
were measured over a time period of 20 min after a sta-
bilisation period of approximately 5 min. The gluteus
muscle of the experimental animal served as a control
site after measurements to verify the proper function of
the Licox® probe.
Statistics
All values are presented as mean ± SD unless otherwise
stated. Non-parametric one-way ANOVA (Kruskal-
Wallis test) with Dunn’s post hoc test was used for
statistical evaluation of CD31, Ki67, GLUT1, HIF1,
necrosis, [
18F]FDG uptake, amount of cells and pO2
values. One-way ANOVA with Tukey’s post hoc test was
used for statistical evaluation of plasma glucose levels
and [
18F]EF5 uptake. The above statistical tests were
performed using GraphPad Prism version 5.01 for Win-
dows (GraphPad Software, San Diego, CA, USA), based
on the distribution of the data (normal or nonpara-
metric) and sample size. A p-value less than 0.05 was
considered statistically significant.
Results
Effects of FGF8b and VEGF on tumour growth and
morphology
In order to study the roles of FGF8b and VEGF in PC-3
tumours, we used xenografts of PC-3 cells ectopically
expressing FGF8b and VEGF. Parental PC-3 cells do not
express detectable levels of FGF8b [38] but they express
VEGF at a low level (Figure 1). PC-3 cells transfected
with FGF8b have been reported previously [38]. To
obtain VEGF overexpressing PC-3 tumours, the cells
were stably transfected with the expression vector
pcDNA3.1(+) containing human VEGF cDNA at an
ECORI site. PC-3 cells transfected with empty vectors
were used as controls (mock). Expression of VEGF in
the isolated clones was confirmed by Western blot ana-
lyses (Figure 1) and Northern blot analyses (data not
shown). Several clones positive for VEGF were obtained,
and one clone (PC-3/VEGF3, later called VEGF) was
selected for in vivo studies.
Tumour growth associated with PC-3/FGF8b, PC-3/
VEGF and PC-3/mock cells was studied by inoculating
t h e ms . c .i nt h eb a c ko ft h en e c k so fn u d em i c e .T h e
average growth (mean ± SEM) of FGF8b, VEGF and
mock tumours is shown in Figure 2A. Mock-transfected
cells produced only small tumours (749 ± 19 mm
3),
whereas FGF8b and VEGF tumours grew larger (3436 ±
41 mm
3 and 4036 ± 51 mm
3, respectively) during the 6
and 4-week study periods, respectively (p < 0.001).
Both FGF8b and VEGF tumours showed strong angio-
genic morphology. They were reddish in colour and
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rhagic. The morphology of mock tumours was solid,
homogeneous and similar to parental PC-3 tumours.
Morphological examination of the H&E-stained sections
showed a rich capillary network and large sinusoid-like
vessels, especially in VEGF tumours (Figure 2B). Capil-
laries in FGF8b tumours looked more aberrant, contain-
ing large cisternal spaces filled with blood (Figure 2B).
The number of capillaries was modest in mock tumours
(Figure 2B). Vascularisation was verified using immuno-
histochemical staining for the endothelial marker CD31
and this procedure confirmed the differences in blood
capillary density between these three different tumour
types (Figure 2C). Significantly increased density of
capillaries (mean ± SEM, p < 0.001) was seen in both
FGF8b (51 ± 27 μm/mm
2) and VEGF (97 ± 4.51 μm/
mm
2) tumours compared with that found in the mock
tumours (36 ± 21 μm/mm
2, Figure 2C-D).
The relative area of necrosis was measured in H&E-
stained tumour sections. The data demonstrated that
t h er e l a t i v ea r e ao fn e c r o s i sw a sl a r g e ri nt h eF G F 8 b
tumours than in the VEGF (p < 0.05) or mock (p <
0.01) tumours (Figure 2E).
Cell cycle analysis and proliferation
Cell cycle phases of FGF8b, VEGF and mock tumours
were determined using flow cytometry. These analyses
revealed a higher number of S-phase cells in both FGF8b
(21%) and VEGF (16%) tumours compared with mock
tumours (12%) (data not shown). Immunohistochemical
staining of tumour sections for Ki67 confirmed these find-
ings (Figure 3), showing a significantly higher proliferation
rate of FGF8b and VEGF tumours compared with that of
mock tumours (p < 0.001). The percentage of Ki67-posi-
tive cells per mm
2 w a s2 6±1 1 ,3 3±1 0a n d1 0±7i n
FGF8b, VEGF and mock tumours, respectively (Figure 3).
Perfusion and oxygenation status of tumours
The labelling intensity of the fluorescent perfusion mar-
ker Hoechst 33342 displayed distinct differences in per-
fusion patterns among the tumours. Labelling intensity
was very weak in FGF8b tumours, indicating poor perfu-
sion. As expected, the intensity was strongest in the
VEGF tumours (Figure 4A), where signals were detected
in both central and peripheral areas, suggesting that
VEGF tumours are well perfused. Labelling intensity was
modest in the mock tumours.
The nitroimidazole family compound EF5 forms cova-
lent bonds with cellular macromolecules under hypoxic
conditions, and therefore tends to accumulate at hypoxic
sites [45,46]. The intratumoral distribution of [
18F]EF5
determined by digital autoradiography in tumour sec-
tions showed a wide variation in the hotspot areas inside
tumours (Figure 4B). The uptake pattern was very similar
with that we have earlier detected and reported in regard
to other hypoxia tracers [47]. It was not possible to ascer-
tain clear divisions based on the intratumoral uptake pat-
tern of [
18F]EF5 according to tumour size, or the
expression levels of the studied growth factors. In gen-
eral, however, some distinguishable trends were detected.
Variation in the intratumoral distribution of [
18F]EF5 in
smaller tumours (~200 mg) was similar (data not shown)
in all groups. Larger tumours (~500 mg) tend to show
more uniformly distributed hotspots of [
18F]EF5 uptake
in VEGF-expressing tumours, whereas uptake of [
18F]EF5
was primary located in peripheral parts of FGF8b- and
mock-tumours (Figure 4B). The accumulation of [
18F]
EF5, in whole tumours was measured after a distribution
time of 120 min. As shown in Figure 4C, a significantly
lower T/B uptake ratio (p <0 . 0 5 )o f[
18F]EF5 was found
in VEGF tumours (1.45 ± 0.37) compared with that mea-
sured in mock tumours (1.81 ± 0.45). The mean T/B
uptake ratio (1.97 ± 0.73) of [
18F]EF5 in FGF8b tumours
was not significantly different compared to VEGF or
mock tumours (Figure 4C).
In order to confirm these findings, we measured the
intratumoral partial pressure of oxygen (pO2)u s i n ga
Licox® Revoxode CC1.2 polarographic probe (Figure 4D).
Significantly lower (p <0 . 0 0 1 )m e a np O 2 values were
measured in both FGF8b and mock tumours (2.3 ± 0.6
mmHg and 1.3 ± 0.3 mmHg, respectively) compared
with that in VEGF tumours (17.4 ± 2.2 mmHg). The pO2
value of the gluteus muscle, measured as a control, was
45 mmHg (data not shown).
Figure 1 Expression of VEGF after transfection of PC-3 cells
with VEGF or mock expression vectors. Western blot analysis of
conditioned medium of PC-3/VEGF cell clones revealed several
clones positive for 23 kD VEGF protein. The larger bands at
approximately 60 kD may represent cleaved formes of larger splice
variants in these cells. The expression level in mock cells was very
low. One PC-3/VEGF clone (PC-3/VEGF3) and one PC-3/mock clone
(PC-3/mock2) were selected for in vivo studies.
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Page 5 of 14Figure 2 Growth and morphology of FGF8b, VEGF and mock tumours. A, Growth of subcutaneous FGF8b, VEGF and mock tumours (n =
30, n = 22 and n = 14, respectively). Tumour diameter in 2 perpendicular dimensions was measured once a week and tumour volume was
calculated according to the formula V = (π/6)(d1 ×d 2)
3/2 and presented as a function of time (mean ± SEM). Differences in tumour volumes
between the groups were significant at all time points between 2 and 4 weeks (p < 0.001). B, H&E staining of representative FGF8b, VEGF and
mock tumours (Bar 200 μm). C-D, The density of CD31-positive blood capillaries (μm/mm
2) was counted in a blinded manner from 3 fields of
the FGF8b, VEGF and mock tumours (51 ± 27 μm/mm
2, n = 18, 97 ± 4 μm/mm
2, n = 72, and 36 ± 21 μm/mm
2, n = 49, respectively), *p < 0.05,
***p < 0.001 (Bar 200 μm). E, The relative area of necrosis was counted in a blinded manner from 3 fields in FGF8b (n = 6), VEGF (n = 6) and
mock (n = 6) tumours, *p < 0.05, **p < 0.01.
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FGF8b and mock tumors were also detected by immunos-
taining of hypoxia-inducible factor (HIF1a) [48,49]. As
shown in Figure 5, the areas staining strongly for HIF1a
showed little immunopositivity for Ki67 whereas the areas
with Ki67 positive cells did not markedly stain for HIF1.
Metabolic activity of tumours
In order to evaluate the metabolic activity of FGF8b-
and VEGF-expressing tumours, we measured the uptake
of [
18F]FDG-derived radioactivity. The intratumoral dis-
tribution of [
18F]FDG determined by digital autoradio-
graphy showed uniformly distributed uptake in tumours
( F i g u r e6 A ) .W ef o u n das i g n i f i c a n t l yl o w e r( p < 0.05)
T/B uptake ratio of [
18F]FDG in FGF8b tumours (7.4 ±
0.7) compared with that seen in VEGF and mock
tumours (14.3 ± 8.9 and 17.8 ± 9.3, respectively), as
shown in Figure 6B. The intracellular [
18F]FDG-6-P (the
main metabolite of [
18F]FDG, which is trapped inside
the cell) was detected by radioHPLC. The amount did
not differ between the tumour groups (data not shown).
The mean plasma glucose level varied from 7.9 to 10.6
mmol/L and was not significantly different in the three
groups of tumour-bearing mice.
Since morphological studies indicated a lower num-
ber of cells in FGF8b tumours, which would affect the
relative level of [
18F]FDG uptake, we evaluated cellular
density in the different tumour models by flow cyto-
metry. Enumeration analysis showed that indeed
FGF8b tumours contained fewer cells/cm
3 than VEGF
and mock tumours (Figure 6B). A similar result was
obtained by counting nuclei per field in H&E-stained
sections (data not shown). When the [
18F]FDG uptake
(percentage of injected dose per gram tissue) was nor-
malised to cell number, the differences between FGF8b
and mock tumours disappeared, and according to the
normalised data, the uptake was smallest in VEGF
tumours (Figure 6B). Immunohistochemical staining of
GLUT1 (Figure 6C) correlated with the uptake of [
18F]
FDG, showing a trend towards a lower expression pat-
tern of GLUT1 in VEGF tumours compared to mock
tumours (p < 0.05).
Figure 3 The effect of ectopic FGF8b and VEGF on proliferation. Ki67 immunostaining of FGF8b (n = 40), VEGF (n = 5) and mock (n = 23)
tumours (Bar 200 μm). The relative number of Ki67-positive cells in tumours was counted in a blinded manner in 3 fields per tumour and the
results were expressed as percentage of positive cells per mm
2. There were significantly more proliferative cells (p < 0.001) in both FGF8b and
VEGF tumours compared with mock tumours.
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Tumour vasculature provides necessary oxygen and
nutrients for tumour growth, but it also plays a major
role in metastatic spread. In prostate cancer, VEGF-
mediated angiogenesis has proved to be important for
tumour growth and metastasis [10,50]. VEGF receptors
are overexpressed in prostate cancer and plasma levels
of VEGF are raised in metastatic disease compared
with localised disease or healthy controls. Alterations
in the vascular supply influence the tumour microen-
vironmental conditions, leading to changes in blood
flow, pH, glucose metabolism and oxygenation, which
all may have significant effects on the responses of
tumours to therapy [5]. Prostate tumours are typically
very hypoxic. Hypoxia is known to induce a more
aggressive phenotype, which increases metastatic
potential, promotes tumour progression and limits the
effectiveness of radiation therapy [2,51]. Tumour cells
generally show increased glycolysis, even under aerobic
conditions, and a rough correlation between the degree
of malignancy and glycolytic rate has long been recog-
nised [52].
Figure 4 Perfusion and oxygenation status of tumours. A, Labelling with the perfusion marker Hoechst 33342 showed that the flow in blood
vessels was better in the VEGF tumours compared with the FGF8b and mock tumours, where Hoechst 33342 labelling was detected only in the
tumour periphery (Bar 200 μm). Examples of the intratumoral distribution of [
18F]EF5 in FGF8b, VEGF and mock tumour sections are shown in B.
FGF8b and mock tumours showed mainly peripherally located uptake of [
18F]EF5, whereas uptake into VEGF tumours was more uniform
throughout the tumours. Uptake intensity is not comparable between these images, since they were not corrected for injected dose or cross-
calibrated between separate studies. C, The tumour-to-blood (T/B) uptake ratio of [
18F]EF5 (T/B ratio) in FGF8b (n = 11), VEGF (n = 12) and mock
(n = 29) tumours is expressed as mean ± SD. Accumulation of [
18F]EF5 was significantly lower (p < 0.05) in VEGF tumours compared with mock
tumours, whereas no significant difference in T/B ratio was seen between FGF8b and mock tumours. Partial pressures of oxygen (pO2) in VEGF
(n = 3), FGF8b (n = 3) and mock (n = 3) tumours are shown in D. The mean values of pO2 measurements are shown as a curve. VEGF tumours
were relatively well oxygenated in comparison with FGF8b and mock tumours.
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angiogenesis and tumour oxygenation in stimulation of
growth of PC-3 prostate xenografts representing com-
monly hypoxic prostate cancer. Morphologic evaluation of
PC-3 tumours overexpressing FGF8b, as well as those
over-expressing VEGF, showed angiogenic morphology
overall, compared with mock tumours. According to the
results of our previous studies, FGF8b may be a key regu-
lator of prostate cancer angiogenesis, supporting tumour
growth [20]. We have previously shown that FGF8b
increases angiogenic capacity in breast cancer cells and
increases vessel sprouting in a chorion allantoic membrane
assay [34,35]. In the present study, immunostaining with
the endothelial marker CD31 confirmed that both FGF8b-
and VEGF-expressing tumours had rich networks of capil-
laries, while in mock tumours the capillary network was
sparse and individual capillaries were smaller. However,
the capillary networks in angiogenic FGF8b- and VEGF-
expressing tumours were not similar. Both tumour models
showed large numbers of capillaries, but the capillary net-
work was more distorted and non-continuous in FGF8b
tumours. Areas of cisternal spaces filled with blood were
also detected in FGF8b tumours. The accelerated growth
rate of both FGF8b and VEGF tumours indicated an
increased vessel capacity tos u p p o r ta n dc o n t r i b u t et o
tumour growth. FGF8 has also been shown to stimulate
the rate of proliferation of PC-3 cells in vitro [20,36], while
VEGF is a mitogenic factor affecting endothelial cells only.
In the present study, the number of Ki67-positive cancer
cells was significantly increased in both FGF8b and VEGF
tumours (Figure 3). However, morphological examination
of the tumours revealed significantly widened areas of
necrosis in FGF8b tumours compared with the others. It
has been previously shown that FGFs may not be able to
Figure 5 Relationship between tumour hypoxia and proliferation. Localisation of areas positively stained for HIF1a and Ki67 was visually
detected from microscope images in FGF8b and mock tumours. The arrows show positive HIF1a staining and negative Ki67 staining in A and B,
and C and D. C and D are captions from the indicated areas in A and B, respectively (Bar 200 μm).
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Page 9 of 14induce mature and fully functional capillaries without
synergistic actions of other growth factors [53]. These
findings made us question whether the capillaries in
FGF8b tumours are able to function properly.
The performance of blood capillaries was studied by
means of the perfusion marker Hoechst 33342, which
revealed relatively low perfusion in mock tumours. Func-
tional capillaries were seen only in the periphery of the
tumours and they were sparse in central parts (Figure 4A).
Despite the rich capillary network in FGF8b tumours, very
low perfusion was detected, indicating that the rapid
growth in comparison with mock tumours was caused by
factors other than increased blood flow. It seems that the
number of functional capillaries in FGF8b tumours is
modest. The vessel-like structures could be a consequence
of angiogenic mimicry, and these structures are not able
to maintain proper oxygenation and support intratumoral
cells. On the other hand, the VEGF tumours seemed to
have an adequate number of functional capillaries. VEGF
tumours were properly perfused, not only peripherally but
also in central areas. Accordingly, the area of necrotic tis-
sue in VEGF tumours was negligible.
Because of abnormal vasculature, hypoxia is very com-
mon in solid tumours. Since morphological evaluation
and perfusion studies of the FGF8b tumours indicated
that these vessels were not functioning normally, we
decided to evaluate the proportion of hypoxic cells in the
tumours. We found a significantly reduced T/B uptake
Figure 6 Glucose metabolism. A, Intratumoral distribution of [
18F]FDG-derived radioactivity in tumour sections (FGF8b n =6 ,V E G Fn =6a n d
mock n = 5). Uptake intensity is not comparable between these images, since they were not corrected for injected dose or cross-calibrated
between separate studies. B, Tumour-to-blood (T/B) uptake ratio of [
18F]FDG (T/B ratio) in FGF8b (n = 6), VEGF (n = 6) and mock (n = 5) tumours
is expressed as mean ± SD. The accumulation of [
18F]FDG was significantly lower (p < 0.05) in FGF8b tumours compared with VEGF and mock
tumours. Number of cells/cm
3 was determined using TrueCount tubes and flow cytometry. On the right, we show relative uptake of [
18F]FDG
after balancing the uptake against cell number. C, Immunostaining of the glucose transporter GLUT1 showed decreased staining in VEGF
tumours compared with mock and FGF8b tumours (FGF8b n = 5, VEGF n = 4 and mock n = 7 tumours) (p < 0.05 VEGF vs. mock, Bar 200 μm).
Analysis was carried out in a blinded manner in three representative non-overlapping fields of the tumours, and the data presented as mean ±
SD.
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18F]EF5 in VEGF tumour-
bearing animals, indicating that these tumours are indeed
more perfused and oxygenated than the others (Figure 4).
The intratumoral distribution of [
18F]EF5 was studied
autoradiographically. Uptake of [
18F]EF5 was generally in
accordance with the results of the perfusion study, show-
ing a relatively high level of [
18F]EF5 uptake in large
peripheral regions of FGF8b and mock tumours, whereas
VEGF tumours showed a more uniform uptake, seen as
smaller clusters throughout the tumour.
The partial pressure of oxygen (pO2)s e e ni nh e a l t h y
tissues varies from 95 mmHg in arterial blood to a
mean value of about 40 mmHg in tissues. Usually
hypoxia is defined as an O2 concentration below 10
mmHg and pO2 values less than 5 mmHg are generally
considered as severe hypoxia [2]. According to our oxy-
gen measurements, both the FGF8b and mock tumours
were hypoxic, showing pO2 values of 2.3 ± 0.6 mmHg
and 1.3 ± 0.3 mmHg, respectively, whereas VEGF
tumours were well oxygenated (17.4 ± 2.2 mmHg). Even
if there were intratumoral necrotic areas, the difference
seemed to be significant. Importantly, tumour hypoxia is
generally considered as a poor prognostic factor [54]. In
order to evaluate the hypoxia status of FGF8b and mock
tumours further, we immunostained tumours against
HIF1a, which mediates acute molecular responses to
hypoxia [49]. The HIF1a-positive cells in FGF8b and
mock tumours were seen as hypoxic clusters. When
these clusters were visually evaluated from microscope
images and compared to the expression of Ki67, we
found a negatively related expression pattern.
In order to evaluate the metabolic activity of the
tumours, we used [
18F]FDG, a glucose analogue, that is
trapped inside metabolically active cells in the form of
[
18F]FDG-6-P [55]. As expected, relatively high uptake of
[
18F]FDG was seen in all three tumour models. Surpris-
ingly, the lowest T/B ratio was seen in FGF8b tumours.
This can be partly explained by the lower cell density and
increased intracellular space seen in the FGF8b tumours
compared with the mock and VEGF tumours (Figure 2B
and 6C). When [
18F]FDG uptake was balanced against
cell number, the level of uptake in FGF8b tumours was
similar to that in the mock tumours. Expression of the
glucose transporter GLUT1 was also increased in FGF8b
and mock tumours, which indicates that hypoxic
tumours compensate for their hypoxia by increased glu-
cose consumption [6]. Hypoxic cells often show
enhanced glycolysis to maintain production of energy in
the form of ATP without requiring O2 [6]. The results of
several studies have shown a relationship between [
18F]
FDG accumulation and GLUT1 expression in cancer
[56]. The relationship between hypoxia and glucose
metabolism might, however, be more complicated than is
generally believed [57]. In a study by Rajendran et al. the
authors found a wide variation in the relationship
between hypoxia and energy metabolism in patients with
different forms of cancer [58]. Acute hypoxia can stimu-
late anaerobic glycolysis in normal tissues and also in
some tumours, but it is not a prime cause of glycolysis,
which is the preferred means of energy metabolism in
many tumours under aerobic conditions as well [6]. Glu-
cose metabolism is also influenced by factors other than
hypoxia, such as the number of tumour-infiltrating
immunoreactive cells. Cellular proliferation might be
reduced in chronically hypoxic regions, whereas the pro-
liferation rate can be elevated in non-hypoxic tumour
areas. This kind of cellular stress often activates other
metabolic pathways as well, such as fatty acid synthetase
(FAS) pathways [59]. Enhanced glycerolipid/free fatty
acid cycling, on the other hand, favours tumour cell
growth in environment poor in nutrients [60]. In addi-
tion, the expression of mitogenic FGF8b itself increases
tumour growth. In clinical practice, high metabolic activ-
ity and hypoxia are considered to be characteristics of
aggressive tumours [58]. Increased expression of FGF8b
is known to predict poor clinical outcome of the patient
[17,32] but it remains to be studied whether hypoxic
tumour microenvironment is associated with or contri-
butes to FGF8b-driven tumour progression.
The limitation of our experimental study is that subcu-
taneous tumours instead of orthotopic tumours were
used, which means heterotopic tumour microenviron-
ment for tumour cells. The PC-3 control tumours formed
were, however, hypoxic as clinical prostate tumours are.
Another limitation is that the expression of FGF8b in
PC-3 cells was not endogenous but produced by transfec-
tion of the ectopic gene which did not allow studies on
the possible effects of silencing the gene on tumour
microenvironment. Unfortunately, no prostate cancer
cell line expressing FGF8 is available. Silencing endogen-
ous VEGF would also add to the results of the role of
VEGF in tumour oxygenation and tumour growth in our
model. Additionally, studies of correlations of VEGF,
FGF8 and HIF1 with each other and characteristics of
clinical tumour samples and outcome of prostate cancer
patients would clarify the role and significance of FGF8
in regulation of prostate cancer progression.
Our study revealed that our prostate tumour models
have different profiles as regards hypoxia, perfusion and
metabolism. The relationship between hypoxia and
blood flow seems to be complex, and our results thus
support the theory of variable oxygenation status
coupled to a highly vascular morphology but differential
numbers of functional vessels. Our results also support
earlier evidence that hypoxia and accelerated glycolysis
are common but independent phenomena in a malig-
nant tumour phenotype. Our results are in line with
those of studies on human prostate cancer, where the
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Page 11 of 14expression of FGF-8, VEGF and clinicopathological find-
ings correlate with each other [61]. FGF8b could thus,
alone or combined with other markers, be used as a
prognostic indicator in cases of prostate cancer. It
remains to be studied whether FGF8 expression is able
to contribute to development of resistance to radiation
and cytotoxic therapies of prostate cancer.
Conclusions
Our results suggest that while VEGF-increased prostate
tumour growth is associated with and most probably
caused by increased density and performance of the vas-
cular network. Elevated tumour growth in FGF8b
expressing xenografts is based on stimulated prolifera-
tive activity and increased hypoxia tolerance, which may
promote prostate tumour progression to a more aggres-
sive phenotype associated with resistance to radiation
and cytotoxic therapies.
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